Trust Co. of Toledo NA OH Increases Stock Position in Bristol Myers Squibb Company $BMY

Trust Co. of Toledo NA OH boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 231.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 158,750 shares of the biopharmaceutical company’s stock after buying an additional 110,815 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Bristol Myers Squibb were worth $7,160,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Trifecta Capital Advisors LLC acquired a new stake in Bristol Myers Squibb in the second quarter valued at approximately $25,000. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb during the second quarter valued at $25,000. Harbor Capital Advisors Inc. grew its position in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares during the period. REAP Financial Group LLC increased its stake in shares of Bristol Myers Squibb by 202.8% during the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 428 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC lifted its stake in Bristol Myers Squibb by 66.0% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 231 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Tuesday. Scotiabank reissued a “sector perform” rating and issued a $53.00 price objective (up from $45.00) on shares of Bristol Myers Squibb in a research note on Thursday, December 4th. Morgan Stanley reaffirmed an “underweight” rating and set a $37.00 target price (up previously from $36.00) on shares of Bristol Myers Squibb in a research note on Friday, December 12th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Finally, HSBC reissued a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Six equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $54.62.

Bristol Myers Squibb Trading Up 0.6%

Shares of Bristol Myers Squibb stock opened at $54.63 on Friday. The stock has a 50 day moving average of $48.61 and a 200 day moving average of $47.33. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The firm has a market capitalization of $111.20 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 8.37 and a beta of 0.29. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be issued a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 83.78%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.